About OrphanPacific

Who we are

History

2018
  • Nov Took over the manufacturing and sales of Diazoxide in Japan from MSD K.K.
2018
  • Dec Merged Nagoya office into Tokyo office.
  • Mar Started Rasilez sales.
  • Jan Took over the manufacturing and sales of Rasilez in Japan from Novartis Pharma K.K.
2017
  • Apr Started Diazoxide sales according to sales rights acquisition of Diazoxide from MSD K.K.
  • Mar Terminated co-promotion of Nopicor
2015
  • Oct Started Dantrium and Astomin sales according to manufacture and sales rights acquisition of Dantrium and Astomin from Astellas Pharma Inc.
  • May Relocated the head office to Hamamatsucho Bldg. (Address: 1-1-1 Shibaura, Minato-ku, Tokyo, Japan)
  • Apr Started Somazon sales according to manufacture and sales rights acquisition of Somazon from Astellas Pharma Inc.
  • Apr Sendai Office established
  • Mar Commenced co-promotion of Nopicor(manufactured and distributed by TORAY MEDICAL CO.,LTD.)
  • Jan Sapporo Office established
2014
  • Dec Fukuoka Office established
  • Jul Nagoya Office established
2013
  • Aug Launched Normosang into market
  • Jun Transferred Normosang approval from CMIC to OrphanPacific
  • Jan Launched Buphenyl into market
2012
  • Dec Osaka Office established
  • Nov Transferred Buphenyl approval from CMIC to OrphanPacific
  • May OrphanPacific established

Business Locations

Office

Head Office

Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo, Japan 105-0023

TEL:03-6779-8151
FAX:03-6683-7851

MAP

Tokyo Office

Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo, Japan 105-0023

TEL:03-6779-8151
FAX:03-6683-7851

MAP

Sapporo Office

13F Sapporo Center Bldg., 6-2-2 Kitagojonishi, Chuo-ku, Sapporo, Hokkaido 060-0005

TEL:011-252-2005
FAX:011-252-2010

MAP

Sapporo Distribution center

Sendai Office

Sendai Mark One Bldg. 14F, 1-2-3 Chuo, Aoba-ku, Sendai, Miyagi
980-0811

TEL:022-217-7287
FAX:022-217-7289

MAP

Nagoya Distribution center

Osaka Office

Nakanoshima Central Tower 7F, 2-2-7, Nakanoshima, Kita-ku, Osaka
530-0005

TEL:06-6233-1730
FAX:06-6202-8155

MAP

Fukuoka Office

Fukuoka Asahi Kaikan 9F, 2-8-41 Tenjin, Chuo-ku, Fukuoka 810-0001

TEL:092-735-7150
FAX:092-735-7151

MAP

Structure of OrphanPacific

Organization of OrphanPacific

(As of January 1, 2020)

Organization of OrphanPacific Organization of OrphanPacific

5 strengths of OrphanPacific

5 strengths of OrphanPacific

Business Model

We will achieve orphan drug creation with an innovative business model.

Our group covers the whole spectrum of pharmaceutical activities from development to sales

OrphanPacific was founded by CMIC HOLDINGS, a leading and pioneer contract research organization (CRO) company in Japan, and MEDIPAL HOLDINGS, a leading pharmaceutical products wholesaler with more than 200 facilities across Japan, reaching out to all medical institutions and pharmacies nationwide.
Extensive collaboration with our parent companies which both have robust track records in the medical field allows OrphanPacific to cover the whole spectrum of pharmaceutical activities from development to promotion in Japan.

Business Model

CMIC Group

Pioneer and Largest Full Service CxO Group in Japan

Corporate overview

  • Company name

    CMIC HOLDINGS Co., Ltd.

  • Establishment

    March 14, 1985 in Tokyo

  • Representative Directors

    Kazuo Nakamura, Ph.D., CEO

  • Capital

    ¥3.1 Bil. (US$31 mil.)

  • Business Model

    Pharmaceutical Value Creator (PVC)
    - Maximizing pharmaceutical company’s value
    CRO, CDMO, CSO, Healthcare, IPM

Business Activities of the CMIC Group

Business Activities of the CMIC Group

Contact us

Monday to Friday 9:00 a.m. to 5:30 p.m. on weekdays (Japan time).